Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100PJWU
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥8.4bn2021-01-01 → 2021-09-30Cons.Net sales
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Operating income−¥1.6bn2021-01-01 → 2021-09-30Cons.Operating income
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.4bn2021-01-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥2.6bn2021-01-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Net income−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss
Total assets¥16.5bnat 2022-09-30Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥28.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥20.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-44.792021-01-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥9.752021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥1.1bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-09-30−¥1.5bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2021-01-01 → 2021-09-30−¥21m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥506m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 372
ItemContextValueUnit
Net salesCurrentYTDDuration3389000000JPY
Cost of salesPrior1YTDDuration4571000000JPY
Cost of salesCurrentYTDDuration2912000000JPY
Gross profitPrior1YTDDuration3783000000JPY
Gross profitCurrentYTDDuration476000000JPY
Reversal of provision for sales returns gpPrior1YTDDuration120000000JPY
Reversal of provision for sales returns gpCurrentYTDDuration－JPY
Provision for sales returns gpPrior1YTDDuration77000000JPY
Provision for sales returns gpCurrentYTDDuration－JPY
Gross profit net gpPrior1YTDDuration3826000000JPY
Gross profit net gpCurrentYTDDuration476000000JPY
Selling general and administrative expensesPrior1YTDDuration5405000000JPY
Selling general and administrative expensesCurrentYTDDuration3226000000JPY
Operating incomePrior1YTDDuration-1578000000JPY
Operating incomeCurrentYTDDuration-2750000000JPY
Interest income noiPrior1YTDDuration2000000JPY
Interest income noiCurrentYTDDuration2000000JPY
Foreign exchange gains noiPrior1YTDDuration35000000JPY
Foreign exchange gains noiCurrentYTDDuration107000000JPY
Rent income noiPrior1YTDDuration1000000JPY
Rent income noiCurrentYTDDuration1000000JPY
Insurance income noiPrior1YTDDuration－JPY
Insurance income noiCurrentYTDDuration20000000JPY
Recoveries from impaired investments noiPrior1YTDDuration－JPY
Recoveries from impaired investments noiCurrentYTDDuration5000000JPY
Other noiPrior1YTDDuration14000000JPY
Other noiCurrentYTDDuration3000000JPY
Non operating incomePrior1YTDDuration54000000JPY
Non operating incomeCurrentYTDDuration141000000JPY
Interest expenses noePrior1YTDDuration3000000JPY
Interest expenses noeCurrentYTDDuration7000000JPY
Rent expenses noePrior1YTDDuration1000000JPY
Rent expenses noeCurrentYTDDuration1000000JPY
Costs of new facilities not yet in use noePrior1YTDDuration217000000JPY
Costs of new facilities not yet in use noeCurrentYTDDuration－JPY
Plant shutsdown related costs noePrior1YTDDuration637000000JPY
Plant shutsdown related costs noeCurrentYTDDuration242000000JPY
Other noePrior1YTDDuration4000000JPY
Other noeCurrentYTDDuration36000000JPY
Non operating expensesPrior1YTDDuration865000000JPY
Non operating expensesCurrentYTDDuration289000000JPY
Ordinary incomePrior1YTDDuration-2389000000JPY
Ordinary incomeCurrentYTDDuration-2898000000JPY
Gain on sales of investment securities eiPrior1YTDDuration60000000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration60000000JPY
Extraordinary incomeCurrentYTDDuration－JPY
Loss on sales of noncurrent assets elPrior1YTDDuration－JPY
Loss on sales of noncurrent assets elCurrentYTDDuration0JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass